GenMark Diagnostics (NASDAQ:GNMK) versus Its Peers Head-To-Head Review

GenMark Diagnostics (NASDAQ: GNMK) is one of 82 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its rivals? We will compare GenMark Diagnostics to similar companies based on the strength of its risk, profitability, institutional ownership, valuation, analyst recommendations, earnings and dividends.

Institutional and Insider Ownership

51.0% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 7.5% of GenMark Diagnostics shares are held by company insiders. Comparatively, 18.6% of shares of all “Advanced Medical Equipment & Technology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and target prices for GenMark Diagnostics and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GenMark Diagnostics 0 0 5 0 3.00
GenMark Diagnostics Competitors 265 1837 3295 105 2.59

GenMark Diagnostics currently has a consensus target price of $14.40, suggesting a potential upside of 86.29%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 7.15%. Given GenMark Diagnostics’ stronger consensus rating and higher probable upside, equities analysts clearly believe GenMark Diagnostics is more favorable than its rivals.

Profitability

This table compares GenMark Diagnostics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
GenMark Diagnostics -111.96% -109.89% -60.26%
GenMark Diagnostics Competitors -328.59% -36.05% -12.67%

Valuation & Earnings

This table compares GenMark Diagnostics and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
GenMark Diagnostics $50.59 million -$49.93 million -6.39
GenMark Diagnostics Competitors $2.06 billion $438.96 million -75.15

GenMark Diagnostics’ rivals have higher revenue and earnings than GenMark Diagnostics. GenMark Diagnostics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

GenMark Diagnostics has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, GenMark Diagnostics’ rivals have a beta of 0.89, meaning that their average stock price is 11% less volatile than the S&P 500.

Summary

GenMark Diagnostics rivals beat GenMark Diagnostics on 7 of the 12 factors compared.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc. is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology. It offers four Food and Drug Administration (FDA)-cleared diagnostic tests which run on its XT-8 instrument; its Respiratory Viral Panel; its Cystic Fibrosis Genotyping Test; its Warfarin Sensitivity Test, and its Thrombophilia Risk Test. It also offers a Hepatitis C (HCV) genotyping test and associated custom manufactured reagents, as well as a 2C19 Genotyping Test, versions of which are available for use with its XT-8 instrument for research use only (RUO). Its XT-8 and ePlex test cartridges utilize the combination of distinct electrodes and multiple signal probes to detect dozens of target biomarkers from a single sample, thereby enabling highly multiplexed testing.

Receive News & Ratings for GenMark Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply